European Business Summits
info@ebsummit.eu – 0032 (0) 2 645 34 80
TRANSPARENCY REGISTER 268958411031-65
PRIVACY-POLICY | GENERAL TERMS OF SALES
ABOUT
The EHS Task Force has been set up due to the considerable success with the launching of the annual European Health Summit. This platform has been designed to drive policy in the domain of health, aside from organising high-level annual events.
The aim is not only to create a larger healthcare network and provide visibility, but also to be able to steer the process of policy making at the European level and strengthen the link between public and private partnership through the involvement of cross-sectorial stakeholders.
The aim is not only to create a larger healthcare network and provide visibility, but also to be able to steer the process of policy making at the European level and strengthen the link between public and private partnership through the involvement of cross-sectorial stakeholders.
PREVIOUS EDITION SPEAKERS
Sandra Gallina
Director General DG SANTE
István Ujhelyi
Member of the European Parliament
Sirpa Pietikäinen
Member of the European Parliament
Csaba Kontor
Health Attaché, Permanent Representation of Hungary to the European Union
Antonella Cardone
CEO Cancer Patients Europe
Martine Pergent
President of International Patient Organization for Primary Immunodeficiencies (IPOPI)
Lilia Luchianov
Policy Officer, DG SANTE
Heike Prinz
Head of Commercial Operations EMEA for the Pharmaceuticals Division and ExCo Member at Bayer AG
Elizabeth Kuiper
Associate Director at European Policy Centre
Patrick Stockebrandt
Head of Division at the Centre for European Policy
Elisabetta Zanon
Director of EU Public Affairs and Advocacy of the Alliance for Regenerative Medicine (ARM)
Enrico Lugli
Group Leader and Head of Facility at Humanitas Research Hospital
Laura Campo
Executive Director International Corporate Affairs, Alzheimer’s disease, Eli Lilly and Company
Ruediger Gatermann
Senior Director EU Policy Strategy at CSL Behring
Mehul Mehta
Chief Medical Officer, Dentons Global Advisors
Mariam Zaidi
Euronews, Euractiv, CNBC Presenter
Sarah-Taïssir Bencharif
EU Health Journalist
Arnaud Thysen
Director General, European Business Summits
Felicia Balan
Partnership Manager, European Business Summits
Alvaro De Lecea
Project Assistant, European Business Summits
TASK FORCE MEETINGS
10 MAY 2023
Closed meeting
A PHARMA STRATEGY FOR RARE AND NON-COMMUNICABLE DISEASES?
The revision of the EU’s Pharma Strategy offers a once in a generation opportunity to highlight to current shortcomings and opportunities in EU health policy when it comes to rare and non-communicable diseases (cardiovascular disease, diabetes etc.). Given the nature of public-private partnerships in the healthcare landscape, listening to the voices of industry is a key factor when it comes to fostering innovation and translating this into improved patient outcomes.
8 JUNE 2023
Residence Palace, Brussels
European Health Summit Summer Edition
12 SEPTEMBER 2023
Closed meeting
ARTIFICIAL INTELLIGENCE AND THE EUROPEAN HEALTH DATA SPACE
AI offers unprecedented opportunities for healthcare, such as reduced costs, increased automation and rapid data processing. On the other hand, questions of data privacy, bias and vulnerabilities may also increase health inequalities. As the EU moves towards the implementation of the EHDS, engaging with stakeholders and ensuring that opportunities can be properly harnessed will be essential for its success.
8 NOVEMBER 2023
Closed meeting
How will the EU pharmaceutical legislation affect competitiveness and innovation in Europe?
As the evolution of the EU pharmaceutical legislation is still being addressed by the stakeholders involved in the sector, some concerns about its potential impact on investment, innovation, and market conditions have been raised. Within the industry, there is apprehension that the regulatory frameworks proposed may pose challenges, potentially hindering investment and innovation, which could, in turn, affect Europe’s competitiveness and attraction compared to its global counterparts. The question now is which points of the pharmaceutical legislation should be revitalised to not only attract investment and stimulate innovation but also to safeguard Europe’s competitiveness in the global market, improve access to medicines and ensure the well-being of the patients.
Have a question? Contact our team!
